Drug induced myopathies

Practical Neurology

Volumn 6, Issue 1, 2006, Pages 4-13

  Mastaglia, F L ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOCAPROIC ACID; AMIODARONE; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; ATORVASTATIN; CARDIOVASCULAR AGENT; CERIVASTATIN; CHLOROQUINE; COLCHICINE; DEXAMETHASONE; EMETINE; ETRETINATE; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; NICOTINIC ACID; PENICILLAMINE; PERHEXILINE; PREDNISOLONE; PREDNISONE; ROSUVASTATIN; SIMVASTATIN; STEROID; STREPTOKINASE; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE DISEASE; CLINICAL FEATURE; CORTICOSTEROID INDUCED MYOPATHY; DERMATOMYOSITIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; EOSINOPHILIA MYALGIA SYNDROME; FASCIOTOMY; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MITOCHONDRIAL MYOPATHY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; MYOPATHY; MYOTONIA; PHYSIOTHERAPY; POLYMYOSITIS; QUADRIPLEGIA; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT;

EID: 32444431509     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2006.088278     Document Type: Review

References (44)

1. Argov Z, Mastaglia FL. Drug-induced neuromuscular disorders in man. In: Walton J, Karpati G, Hilton-Jones D, eds. Disorders of voluntary muscle, 6th edn. Edinburgh, UK: Churchill Livingstone, 1994:989-1029.
2. Sieb JP, Gillessen T. latrogenic and toxic myopathies. Muscle Nerve 2003 27:142-56.
3. Baker SK, Goodwin S, Sur M, et al. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004:30:799-802.
4. Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989:86:481-3.
5. Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001:12:565-9.
6. Gotto AM. Safety and statin therapy. Arch Intern Med 2003:163:657-9.
7. Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neural 2004;61:889-92.
8. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
9. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. New Engl J Med 2002:346:539-40.
10. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
11. Alsheikh-Ali AA, Ambrose MS. Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005:111:3051-7.
12. Worz CR, Bottorff M. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Expert Opin Pharmacother 2001;2:1119-27.
13. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004:58:56-60.
14. Tomlinson B, Chan P, Lan W. How well tolerated are lipid-lowering drugs? Drugs Aging 2001:18:665-83.
15. Argov Z. Drug-induced myopathies. Curr Opin Neurol 2000:13:541-5.
16. Fux R, Morike K, Gundel UF, et al. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004:140:671-2.
17. Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004;30:803-7.
18. Mastaglia FL Toxic myopathies. In: Rowland LF, S. DiMauro S, eds. Handbook of clinical neurology. The Netherlands: Elsevier Science Publishers BV, 1992:595-622.
19. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engll Med 1990;322:1098-105.
20. Panegyres PK, Papadimitriou JM, Hollingsworth PN, et al. Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment. J Neurol Neurosurg Psychiatry 1990;53:649-55.
21. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5.
22. Tao SH, Bolger PM. Hazard assessment of germanium supplements. Regul Toxicol Pharmacol 1997:25:211-19.
23. Carroll GJ, Will RK, Peter JB, et al. Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 1987;14:995-1001.
24. Hengstman GJ, Vogels OJ, ter Laak HJ, et al. Myositis during long-term interferon-alpha treatment Neurology 2000:54:2186.
25. Di Muzio A, Di Guglielmo G, Feliciani C, et al. Inflammatory myopathy after intravenous streptokinase. Muscle Nerve 1997;20:619-21.
26. Kaufman LD. Neuromuscular manifestations of the L-tryptophan-associated eosinophilia-myalgia syndrome. Curr Opin Rheumatol 1990:2:896-900.
27. Belongia EA, Hedberq CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323;357-65.
28. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001;124:1821-31.
29. Rannels SR, Rannels DE, Pegg AE, et al. Glucocorticoid effects on peptide-chain initiation in skeletal muscle and heart. Am J Physiol 1978;235:E134-9.
30. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology 1991;41:1235-9.
31. Bowyer SL LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985:76:234-42.
32. Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: recognition of a characteristic larynaeal abnormality. Thorax 1983;38:813-21.
33. Mastaglia FL, Laing NG. Investigation of muscle disease. J Neurol Neurosurg Psychiatry 1996:60:256-74.
34. Hickson RC, Davis JR. Partial prevention of glucocorticoid-induced muscle atrophy by endurance training. Am J Physiol 1981:241:E226-32.
35. Van Marle W, Woods KL. Acute hydrocortisone myopathy. BMJ 1980:281:271-2.
36. Campellone JV, Lacomis D, Kramer DJ, et al. Acute myopathy after liver transplantation. Neurology 1998;50:46-53.
37. Perea M, Picon M, Miro O, et al. Acute quadriplegic myopathy with loss of thick (myosin) filaments following heart transplantation. J Heart Lung Transplant 2001;20:1136-41.
38. Comi G, Testa D, Cornelio F, et al. Potassium depletion myopathy: a clinical and morphological study of six cases. Muscle Nerve 1985:8:17-21.
39. Rutkove SB, De Girolami U, Preston DC, et al. Myotonia in colchicine myoneuropathy. Muscle Nerve 1996:19:870-5.
40. Sholl JS, Hughey MJ, Hirschmann RA. Myotonic muscular dystrophy associated with ritodrine tocolysis. Am J Obstet Gynecol 1985:151:83-6.
41. Bretag AH, Dawe SR, Moskwa AG. Chemically induced myotonia in amphibia. Nature 1980;286:625-6.
42. Lacomis D. Case of the month. June 1996-anorexia nervosa. Brain Pathol 1996:6:535-6.
43. Mastaglia FL, Papadimitriou JM, Dawkins RL, et al. Vacuolar myopathy associated with chloroquine, lupus erythematosus and thymoma. Report of a case with unusual mitochondrial changes and lipid accumulation in muscle. J Neurol Sci 1977:34:315-28.
44. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000:27:2927-31.